March 2017 DAWN Software E-Newsletter
Software for Rheumatology, Gastroenterology, Dermatology and Respiratory
In this issue:
DAWN Regional User Workshop (London) - Proceedings Document
As you will be aware, 4S DAWN holds regional workshops for customers from across the UK to meet and share best practice for using their DAWN systems and to discuss common challenges faced by their services.
The latest meeting, held in London was a great success and you can read the Proceedings Document from the workshop which covers the presentations given by both current customers and 4S DAWN staff.
I hope that you find the document of interest and don’t forget that you can see presentation summaries from previous meetings on the 4S DAWN website: http://www.4s-dawn.com/products/rheumatology/dawn-rh-user-group/
Come and visit us at the BSR, Birmingham
4S DAWN will be exhibiting at this year’s British Society of Rheumatology meeting in Birmingham from April 25th - 27th.
Come and visit us at Stand R22 and take a look at the latest product developments within DAWN RH and speak to members of the 4S DAWN team who will be happy to discuss the product and offer demonstrations.
We look forward to seeing you there!
Reporting from your DAWN system
DAWN customers often find that querying their database can help with communication to certain patients by finding a list of those currently treated.
Identifying patients who are stable or who may be suitable for research projects is also important. Reporting from DAWN can help monitor statistics on patients started and stopped in a period or on a certain drug.
The output can be a simple chart of results:
or a list of patients:
The Reports section in DAWN is useful for reviewing your system to see which users have certain permissions when they access your DAWN database.
Data from DAWN reports can be created as a file for later analysis with Excel or other tools. Options for simply viewing the report or printing are also available.
Contact the 4S DAWN team for more information at firstname.lastname@example.org.
Boost team work with electronic referrals
Referring a patient to a consultant for an opinion should be quick, efficient and traceable. If you don't have time to chase your colleagues between clinics but you feel an opinion would keep your patient safe, consider team-working using electronic referrals in DAWN.
DAWN's electronic referral functionality enables you to make referrals quickly and easily, making your workflow more efficient and saving you time.
Contact email@example.com to request a short internet demonstration.
Expand your capabilities with DAWN
There are a number of add-on modules available for DAWN designed to help customers expand their capabilities and improve productivity and efficiency. The following modules are available for DAWN systems:
- Interfaces - test results, demographics, admission and discharge, GP summary, medications and many more
For more information about any of the additional modules, contact the 4S DAWN team today - firstname.lastname@example.org.
As the range of application areas covered by 4S DAWN Clinical Software increases, there has been lots of interest in using DAWN within other departments and many customers now have a number of DAWN systems installed within their hospital/Trust.
The DAWN software also covers the following areas:
If you or any of your colleagues would be interested in learning more about any of the areas above, contact the 4S DAWN team today at email@example.com to discuss your requirements and see a demonstration of the software in action.
- Anaemia Management
- Clinical Haematology
- Heart Failure
- Multiple Sclerosis
- VTE Diagnosis and Assessment
In the news.....
RA Progresses More Slowly Now than 20 Years Ago
Patients with early rheumatoid arthritis (RA) with onset in the modern era had significantly lower baseline and annual rates of radiographic disease progression versus those with onset before 2001, researchers in England reported.
Among two cohorts of RA patients spanning 25 years, 74% of patients recruited from 1986 to 2001 progressed on average ≥5 units per year over 5 years of follow-up, compared with only 27% of patients recruited from 2002 to 2013, according to Lewis Carpenter, PhD, from the Centre for Clinical and Health Service Research at the University of Hertfordshire in Hatfield, and colleagues.
Biosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation
Biologic drugs such as infliximab and other anti–tumor necrosis factor monoclonal antibodies have transformed the treatment of immune-mediated inflammatory conditions such as Crohn's disease and ulcerative colitis (collectively known as inflammatory bowel disease [IBD]).
Recent or impending expiration of patents for several biologics has led to development of biosimilar versions of these drugs, with the aim of providing substantial cost savings and increased accessibility to treatment.
To date, most anti–tumor necrosis factor biosimilars have been tested in trials recruiting patients with rheumatoid arthritis. Concerns have been raised regarding extrapolation of clinical data obtained in rheumatologic populations to IBD indications.
Novel Mechanism Induces Joint Destruction in Rheumatoid Arthritis
A mechanism that plays a role in joint inflammation in patients with rheumatoid arthritis (RA) has been identified, which could present a new treatment target.
Destruction to bone and cartilage is one of the key manifestations of RA. Scientists have known the role of T helper (Th)17 cells in these processes, but the role of IL-21-producing T cells has not been as clear. In a study published in the Journal of Leukocyte Biology, sought to examine the role of IL-21 in RA by focusing on the functional characteristics of synovial IL-21/TNF-producing CD4 T cells.